Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 186

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 186
---
 statements. We will remain a smaller reporting company for each fiscal year in which (1) the market value of our ordinary shares held by non -affiliatesis less than $250 million as of the end of the previous year’s second fiscal quarter, or (2) our annual revenues are less than $100 million during the previous completed fiscal year and the market value of our ordinary shares held by non -affiliatesis less than $700 million as of the end of the previous year’s second fiscal quarter. LEGAL PROCEEDINGS There is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such, and we and the members of our management team have not been subject to any such proceeding in the 12 months preceding the date of this prospectus. 118

Management DIRECTORS AND EXECUTIVE OFFICERS Our directors and executive officers upon the effective date of the registration statement of which this prospectus forms part will be as follows:

| Name              |     | Age |     | Title                                                    |
| Lynn Stockwell    |     |  68 |     | Chief Executive Officer and Executive Chair of the Board |
| Glenn Worman      |     |  65 |     | Chief Financial Officer                                  |
| Catherine Do      |     |  45 |     | Director Nominee                                         |
| G. Sridhar Prasad |     |  61 |     | Director Nominee                                         |
| Myron W. Shulgan  |     |  78 |     | Director Nominee                                         |

Lynn Stockwellhas been our Chief Executive Officer since September 2024 and Executive Chair of the Board since June 2024 and is the managing member of the sponsor. Ms. Stockwell is the founder of Bright Green Corporation (Nasdaq: BGXX), where she has been a board member since its inception in 2019 and Chair of the Board since February 2024. From 2015 to 2020, Ms. Stockwell was Managing Member of Bright Green Innovations, LLC, a pioneering plant -basedpharmaceutical research company recognized for its compliance with federal legal standards. In this role, Ms. Stockwell expertly managed business, industry, and medical research relationships. In addition to her leadership roles, Ms. Stockwell has also served as a director at a hospital, where she spearheaded fundraising initiatives advocating for the use of natural additives as a safer alternative to opioids. Her dedication extends to her sponsorship